Xanthones and anthraquinones from the soil fungus <i>Penicillium</i> sp. DWS10-P-6

Wang, Yajing; Liu, Chun-yue; Feng, Yi-xuan; Zhang, Feng-Xiang; Chang, Li Fung; Pei, Yue‐Hu

doi:10.1039/d0ra08141h

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…strain DWS10-P-6. Both oxisterigmatocystins exhibited weak anticancer activity against PC-3, MDA-MB-231, and HL-60 cancer cell lines in the IC 50 range of 12.0-50.0 µM [71]. The chemical structures of the aforementioned xanthones are shown in Figure 5, while the summary of the anticancer activity of isolated xanthone derivatives is listed in Table 2.…”

Section: Isolation Of Xanthone Derivativesmentioning

confidence: 99%

An Update on the Anticancer Activity of Xanthone Derivatives: A Review

et al. 2021

View full text Add to dashboard Cite

The annual number of cancer deaths continues increasing every day; thus, it is urgent to search for and find active, selective, and efficient anticancer drugs as soon as possible. Among the available anticancer drugs, almost all of them contain heterocyclic moiety in their chemical structure. Xanthone is a heterocyclic compound with a dibenzo-γ-pyrone framework and well-known to have “privileged structures” for anticancer activities against several cancer cell lines. The wide anticancer activity of xanthones is produced by caspase activation, RNA binding, DNA cross-linking, as well as P-gp, kinase, aromatase, and topoisomerase inhibition. This anticancer activity depends on the type, number, and position of the attached functional groups in the xanthone skeleton. This review discusses the recent advances in the anticancer activity of xanthone derivatives, both from natural products isolation and synthesis methods, as the anticancer agent through in vitro, in vivo, and clinical assays.

show abstract

Section: Isolation Of Xanthone Derivativesmentioning

confidence: 99%